丸善雄松堂株式会社
学術情報ソリューション事業部
法律情報営業部

〒160-0002
東京都新宿区四谷坂町10-10
Tel: 03-6367-6120
Fax: 03-6367-6215

※2018年5月7日より電話・Fax番号が変わりました。

ご注文に際して

個人情報保護方針

コーポレートサイト

書影

特許ライセンス契約 解説と書式

Patent Licensing Transactions

Eric Bensen, Harold Einhorn

3 vols. Looseleaf. 1968 to date.(追録年2回)

Matthew Bender. ISBN: 9780820515311

¥381,271

在庫あり

特許ライセンス契約の締結に関して考慮しなければならない点を、最新の制定法・判例を交えながら具体的に解説。多種多様な状況や権利対象を想定したライセンス契約の書式を100種以上収録しています。

Vol.1 ■COMMENTARY■ 解説編 ライセンス交渉における原則と手続について詳説。
概論/主な権利と義務/ロイヤルティ/契約期間と契約の終了/国際ライセンス/政府・大学機関とのライセンシング/バイオテクノロジー・ライセンシング/治験実施契約/ミスユース・反トラスト法/タックス・プランニング/特許訴訟の和解合意/共同抗弁 (Joint Defense)/破産における特許ライセンス、等

Vol.1A&2 ■FORMS & APPENDIX■ 書式と資料 多種多様な契約書式と関連条文を収録。
書式例) 排他的・非排他的ライセンス/フランチャイズ/クロス・ライセンス/サブ・ライセンス/従業員発明/特許権譲渡/機密保持契約/商標/著作権/ソフトウェア/キャラクター/共同抗弁契約 (JDA)/シュリンクラップ、等

【Table of Contents】

1. General Considerations

2. Principal Rights and Obligations

3. Royalty

4. Duration and Termination

5. Foreign Licensing

6. Government and University Licensing

6A. Biotechnology Licensing

6B. Clinical Trial Agreements

7. Misuse and Antitrust Considerations

8. Tax Planning for Patents, Know-How and Trademarks

9. Tax Planning for Foreign Licensing

10. Patent Settlement Agreements

11. Joint Defense Agreements

12. Patent Licenses in Bankruptcy

13. Overview of Core Patent Law Principles

FORMS

A1. Mutual Release and Cross Patent License Agreement (Annotated)

A2. Exclusive Patent and Trade Secret License – Joint Venture (Annotated)

A3. Development and Assignment Agreement (Annotated)

1.01. Exclusive License Agreement with Owner of Secret Process; Royalty Based on Gross Profits

1.02 Employment Agreement Incorporating Exclusive License of Employee’s Patents

1.03 License of Machines and Secret Process by Exclusive Licensee; Profit-Sharing Basis; Letter of Agreement

1.04 Exclusive License Agreement; Issued Improvement Patent for Apparatus

1.05 Exclusive License Agreement for Secret Process; Licensee to Apply for Patent

1.06 Invention Disclosure Agreement; Patent Applied for; Option to Acquire Exclusive License

1.07 Mutual Release and Cross Patent License Agreement

2.01 Nonexclusive License Agreement; Method of Geophysical Exploration

2.02 Nonexclusive License Agreement; Patent Structural Member

2.03 Nonexclusive License of Pending Chemical Patent and Related Know-How

2.04 Nonexclusive License of Chemical Compound; C Limitation on Method of Distribution

2.05 Letter Initiating Negotiation of Nonexclusive License

2.06-2.11 Pro Forma Nonexclusive License

2.12 Exclusive License of Know-How (Pharmaceutical Compound and Process for Making Same)

3.01 Sample Provisions for License Agreements

3.02 License and Technical Assistance Agreement; The Netherlands; Sales and/or Manufacturing Rights Included

3.03 Process Guarantee

4.01 Franchise Agreement; Computerized Legal Research Services

5.01 Foreign License Agreement

6.01 Lease Agreement; Australia

6.02 Equipment Lease Agreement

7.01 Cross-Licensing Agreement for an Industry

7.02 Cross License Agreement (Alternate Form)

8.01 License Agreement for Sublicensing Outside United States and Canada

8.02 License and Power to Sublicense under Patent Applications

8.03 Power to License and Sublicense

9.01-9.03 Agreement Settling Interference

10.01-10.02 Agreement between Employer and Employee for Assignment of Inventions to Employer

10.03-10.05 Employment Agreement

10.06 Employee Agreement

11.01 Technical Service Agreement; Venezuela

11.02 Technical Assistance Agreement; Spain

11.03 Tolling Agreement (Processing Agreement)

11.04 Tolling Agreement (Pending Litigation)

11.05 Tolling Agreement with Government Agency

12.01 Patent Rights Clause; United States Government Research and Developments Contract

12.02-12.03 Patent Rights Assignment

12.04 Patent Purchase and Assignment Agreement

13.01 Agreement to Form Jointly Owned Company, Japan; License; Technical Assistance Agreement

13.02 Agreement to Form French Limited Liability Company; Operation under License and Technical Assistance Agreement

14.01 Letter Form Confidentiality Agreement

14.02 Personal Confidentiality Agreement

14.03-14.04 Contractor’s Confidentiality Agreement

14.05 Confidentiality Agreement

14.06 Nonanalysis Agreement

14.07 Unsolicited (Non-Confidential) Disclosure Agreement

15.01-15.05 Consulting Agreement

16.01 Hold Harmless

17.01 Power of Attorney

18.01 Trademark License

18.02 Trademark Assignment

18.03-18.04 Trademark License Agreement

18.05 Trademark License (Includes Use of Domain Names)

18.06 Non-exclusive Trademark License (Trademark Owned by Non-Profit Organization)

19.01 University Research Grant

20.01-20.02 Copyright Assignment

20.03 Exclusive Copyright License Agreement between Photographer and Musician

20.04 Combined Trademark and Copyright License Agreement

20.05 Simple Copyright License Relating to Speaking Engagement

21.01-21.02 Software License

21.03 Click-On License Agreement

21.04 Software Sales Representative Agreement

21.05 Software Technical Services Agreement

21.06 Worksheet for Calculating Royalties Based on the Licensee’s Net Selling Price

21.07-21.09 Master Software License Agreement

21.10 Non-Exclusive Database Software License

21.11 Software Licensing Agreement

22.01 License Option by Defaulting Supplier

22.02 Option and License for Chemical Technology

23.01 Character License Agreement

24.01-24.03 Settlement Agreement

25.01-25.03 Sample Development & License Agreement; Pharmaceutical

26.01 Sample Clinical Trial Agreement

26.02 Model Clinical Study Agreement between University and Company

26.03 Clinical Trial Agreement between Collaborator and Research Institution for the Clinical Development of Agent

26.04 More Complex Clinical Trial Agreement for Pharmaceutical Industry Sponsored Research

27.01-27.13 Model Joint Defense Agreement (“JDA”)

28.01 Material Transfer Agreement

28.02 Biological Materials Transfer Agreement

29.01-29.02 Trademark License Agreement

30.01 Supply Agreement (With Patent License Provisions)

31.01 Employee Invention Report (EIR)

31.02 Confidential Disclosure Agreement (CDA)

31.03-31.05 NIH-University

31.06 License Application

31.07 2006 Model NIH Materials Cooperative Research and Development Agreement

31.08-31.10 2009 Model PHS Cooperative Research and Development Agreement

31.11-31.12 Non-Exclusive Patent License Agreement

31.13 Exclusive Patent License Agreement

31.14 Biological Materials License Agreement

31.15 Biological Materials – Internal Use

31.16 Commercial Evaluation License Agreement (CEL)

31.17 PHS Model Agreement for License Amendments

31.18 Material Transfer Agreement for the Transfer of Organisms

31.19 UBMTA Master Agreement

31.21 UBMTA Implementing Letter

31.22 UBMTA Signatories

31.23 W-9 – Request for Taxpayer Identification Number and Certification

32.01 End-User License (Shrink Wrap License)

32.02 Domestic License Agreement (Shrink Wrap License)

32.03 Sample Shrink Wrap License

32.04 End User License

32.05 Software System License

 

Appendix 1: Index to Forms

Appendix 2: Bibliography

Appendix 3: Justice Department Antitrust Guide Concerning Research Joint Ventures

Appendix 4: Selected Portions Of Export Administration Regulations

Appendix 5: Antitrust and Quantitative Restriction Provisions of Common Market Treaty (Articles 28, 29, 30, 81-86, 234, Treaty of Rome, 1957)

Appendix 5A: Technology Transfer Bloc Exemption

Appendix 5B: Joint Research Bloc Exemption

Appendix 6: Report of the Attorney General's National Committee to Study the Antitrust Law (1955)

Appendix 6a1: FTC Antitrust Actions Involving Pharmaceutical Services and Products

Appendix 6a2: Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Summary of Agreements Filed in FY 2004 A Report by The Bureau of Competition

Appendix 7: 37 C.F.R. Part 401--Rights to Inventions made by Nonprofit Organizations and Small Business Firms Under Government Grants, Contracts, and Cooperative Agreements

Appendix 7A United States Code Title 35, Chapter 18, Patent Rights in Inventions Made with Federal Assistance

Appendix 8: Antitrust Guidelines for the Licensing of Intellectual Property

Appendix 8A: Relevant Provisions of the Internal Revenue Code

Appendix 8B: Tax Checklist

Appendix 9: Present Value Table

Appendix 9A: Relevant Provisions of the Internal Revenue Code

Appendix 10: Antitrust Enforcement Guidelines for International Operations Issued by the U.S. Department of Justice and the Federal Trade Commission

Appendix 11: Patents, Pools and Progress (or Why Patent Pools Can Often Be Illegal)

Appendix 12: Guidelines for the Regulation of Unfair Trade Practices with Respect to Licensing Agreements in Japan

Appendix 13: Guidelines for the Regulation of Joint Research and Development Agreements in Japan

Appendix 14: Acts Concerning Prohibition of Private Monopolization and Maintenance of Fair Trade (Japan)

Appendix 15: World Intellectual Property Organization ("WIPO") As of 2005

Appendix 16: World Trade Organization ("WTO") As of June 25, 2004

Appendix 17: The Federal Arbitration Act

Appendix 18: Alternative Dispute Resolution Act of 1998

Appendix 19: United Nations Foreign Arbitral Awards Convention Act (R.S. 1985, c. 16 (2nd Supp.)) Updated to August 31, 2004

Appendix 20: World Intellectual Property Organization Mediation Rules

Appendix 21: WIPO Expedited Arbitration Rules

Appendix 22: Treaty Establishing the European Community, As Amended by Subsequent Treaties, Rome 25 March 1957

Appendix 23: European Patent Organisation Member States

Appendix 24: Act Concerning Prohibition of Private Monopolization And Maintenance of Fair Trade (Act No. 54 of 14 April 1947) (Tentative Translation)

Appendix 25: Canada's Competition Act (R.S.C. 1970) C. C-23 (Renamed by 1986 C. 26 S. 19)

Appendix 26: Monopoly Regulation and Fair Trade Act

Appendix 27A: Brief of Amicus Curiae Licensing Executives Society (U.S.A. & Canada), Inc. In Support of Neither Party

Appendix 27B: Brief of the Boston Patent Law Association as Amicus Curiae in Support of Genentech, Inc., on the Merits

Appendix 27C: Brief for the United States as Amicus Curiae Supporting Petitioner

Appendix 27D: Amicus Brief for Pharmaceutical Research and Manufactures of America Supporting Respondents

Appendix 27E: Brief Amicus Curiae of 3M, General Electric, Procter & Gamble, and E.I. Dupont De Nemours and Company in Support of Respondents

Appendix 27F: Brief Amicus Curiae of The Generic Pharmaceutical Association in Support of Petitioner